Ang Lifesciences reappoints Chetna as Independent Director for 5 years
- Shareholders approved Mrs. Chetna's reappointment as Independent Director for a second five-year term
- New term runs from October 12, 2026, to October 11, 2031
- Meeting adopted FY26 financial statements and ratified cost auditor remuneration for FY27
- 38 members participated in the video-conferenced AGM, satisfying quorum requirements

*this image is generated using AI for illustrative purposes only.
ANG Lifesciences India Limited shareholders approved the reappointment of Mrs. Chetna as an Independent Director for a second term of five years during the company's 20th Annual General Meeting held on September 30, 2026.
The new term commences on October 12, 2026, and extends through October 11, 2031. The appointment was ratified under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, following a prior intimation dated September 7, 2026.
AGM proceedings and resolutions
The meeting was chaired by Managing Director Rajesh Gupta and conducted via video conferencing. Independent Director Sukhpal Singh was granted leave of absence due to unavoidable circumstances, while five other directors, including Wholetime Director and CFO Saruchi Gupta, attended virtually. A total of 38 members participated, satisfying quorum requirements.
Key resolutions passed included:
- Adoption of audited standalone and consolidated financial statements for FY26.
- Re-appointment of Rohit Mittal as a director retiring by rotation.
- Ratification of the cost auditor's remuneration for FY27.
- Re-appointment of Chetna as an independent director.
The company noted that no queries were received from shareholders during the session. The meeting commenced at 12:00 pm and concluded at 12:22 pm.
Director profile and compliance details
Mrs. Chetna (DIN: 08981045) brings extensive experience in corporate law, securities law, SEBI compliances, financial management, accounts, and taxation. Her qualifications include an LLB from Jaipur School of Law, Company Secretary certification from the Institute of Company Secretaries of India, and an MBA in Finance. She is registered in the Independent Director Databank under the Indian Institute of Corporate Affairs.
| Particulars | Details |
|---|---|
| Name | Mrs. Chetna |
| DIN | 08981045 |
| Role | Independent Director |
| Term Start | October 12, 2026 |
| Term End | October 11, 2031 |
| Duration | 5 years |
Disclosure records indicate no relationship between Mrs. Chetna and other Directors or Key Managerial Personnel. She is not debarred from holding the office of Director by any SEBI order or authority.
Voting and compliance
Remote e-voting facilities were available to members from September 27, 2026, to September 29, 2026. Additionally, e-voting was enabled during the AGM for those who had not voted remotely. The scrutinizer, Anil Negi, will submit the consolidated voting results to the stock exchanges within two working days. The results will also be placed on the company's website.
Historical Stock Returns for ANG Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.86% | +7.98% | +33.25% | +112.33% | +27.65% | -84.61% |
How will Mrs. Chetna's continued tenure as an Independent Director influence ANG Lifesciences' strategic compliance posture regarding upcoming SEBI regulatory changes?
What specific governance improvements or board-level initiatives are expected to emerge from the stability provided by the reappointment of key directors for the FY27-FY31 period?
Given the rapid conclusion of the AGM with no shareholder queries, how might this signal affect institutional investor confidence in the company's current communication transparency?


































